N-terminal negatively charged residues in CD3varepsilon chains as a phylogenetically conserved trait potentially yielding isoforms with different isoelectric points: analysis of human CD3varepsilon chains

Nonclinical Pharmacokinetics and Pharmacodynamics Characterization of Anti-CD79b/CD3 T Cell-Dependent Bispecific Antibody Using a Surrogate Molecule: A Potential Therapeutic Agent for B Cell Malignancies

The T cell-dependent bispecific (TDB) antibody, anti-CD79b/CD3, targets CD79b and CD3 cell-surface receptors expressed on B cells and T cells, respectively. Since the anti-CD79b arm of this TDB binds only to human CD79b, a surrogate TDB that binds to cynomolgus monkey CD79b (cyCD79b) was used for preclinical characterization. To evaluate the impact of CD3 binding affinity on the TDB pharmacokinetics (PK), we utilized non-tumor-targeting bispecific anti-gD/CD3 antibodies composed of a low/high CD3 affinity arm along with a monospecific anti-gD arm as controls in monkeys and mice. An integrated PKPD model was developed to characterize PK and pharmacodynamics (PD). This study revealed the impact of CD3 binding affinity on anti-cyCD79b/CD3 PK. The surrogate anti-cyCD79b/CD3 TDB was highly effective in killing CD79b-expressing B cells and exhibited nonlinear PK in monkeys, consistent with target-mediated clearance. A dose-dependent decrease in B cell counts in peripheral blood was observed, as expected. Modeling indicated that anti-cyCD79b/CD3 TDB’s rapid and target-mediated clearance may be attributed to faster internalization of CD79b, in addition to enhanced CD3 binding. The model yielded unbiased and precise curve fits. These findings highlight the complex interaction between TDBs and their targets and may be applicable to the development of other biotherapeutics.

Fate of engineered cerium oxide nanoparticles in an aquatic environment and their toxicity toward 14 ciliated protist species

The potential environmental impacts of engineered cerium oxide nanoparticles (CeO2 NPs) on aquatic organisms have remained largely unknown. Therefore, the laboratory study featured herein was performed to determine the fate of CeO2 NPs in an aquatic environment and their toxicity towards 14 different ciliated protist species at a specified population level. An investigation of 48 h aggregation kinetics in the Dryl's solution showed the CeO2 NPs to be relatively stable. The pH values in three test medium were too far away from PZC, which explained the stability of CeO2 NPs. CeO2 NPs generally elicited more toxicity with increasing NP concentration, following certain dose-response relationships. Nano-CeO2 resulted in greater toxicity in a particle state than when added as bulk material. LC50 values showed a negative correlation with the surface-to-volume ratio for these protists, suggesting that surface adsorption of CeO2 NPs might contribute to the observed toxicity. Additionally, acute toxic responses of 14 ciliated protist species to CeO2 NPs were not significantly phylogenetically conserved. The results of these observations provide a better insight into the potential risks of CeO2 NPs in an aquatic environment.

Biased binding of class IA phosphatidyl inositol 3-kinase subunits to inducible costimulator (CD278)

To better understand T lymphocyte costimulation by inducible costimulator (ICOS; H4; CD278), we analyzed proteins binding to ICOS peptides phosphorylated at the Y(191)MFM motif. Phosphorylated ICOS binds class IA phosphatidyl inositol 3-kinase (PI3-K) p85α, p50-55α and p85β regulatory subunits and p110α, p110δ and p110β catalytic subunits. Intriguingly, T cells expressed high levels of both p110α or p110δ catalytic subunits, yet ICOS peptides, cell surface ICOS or PI3-kinase class IA regulatory subunits preferentially coprecipitated p110α catalytic subunits. Silencing p110α or p110δ partially inhibited Akt/PKB activation induced by anti-CD3 plus anti-ICOS antibodies. However, silencing p110α enhanced and silencing p110δ inhibited Erk activation. Both p110α- and p110δ-specific inhibitors blocked cytokine secretion induced by TCR/CD3 activation with or without ICOS costimulus, but only p110α inhibitors blocked ICOS-induced cell elongation. Thus, p110α and p110δ are essential to optimal T cell activation, but their abundance and activity differentially tune up distinct ICOS signaling pathways.